Treatment patterns and clinical outcomes according to PD-L1 status in >2000 patients with early-stage or metastatic triple-negative breast cancer treated in the real-world setting: VANESSA study results

BACKGROUND: The prognostic effect of PD-L1 status in triple-negative breast cancer (TNBC) is uncertain and little is known about PD-L1-positive prevalence and outcomes in the real-world setting. PATIENTS AND METHODS: The multicentre retrospective observational VANESSA study evaluated the prevalence and impact of PD-L1-positive status in 2054 patients receiving systemic therapy for early-stage or metastatic (e/m)TNBC between 2014 and 2017. PD-L1 expression was assessed locally and centrally on archival samples. Descriptive analyses of demographic and clinicopathological characteristics, treatment patterns and clinical outcomes (extracted from patients' medical records) according to PD-L1 status were prespecified. RESULTS: Among 1902 patients with eTNBC, 681 (36%) received neoadjuvant chemotherapy and 1261 (66%) adjuvant chemotherapy. Demographic characteristics were generally similar regardless of PD-L1 status, but lower-risk tumour characteristics were more common in the PD-L1-positive subgroup. Invasive disease-free and overall survival were more favourable in PD-L1-positive eTNBC. In the mTNBC cohort, 120/145 (83%) patients had de novo mTNBC. Median progression-free survival on first-line treatment was 7.6 months (95% CI: 4.1-15.0) in PD-L1-positive mTNBC (n = 30) and 4.9 months (95% CI: 3.6-6.1) in PD-L1-negative mTNBC (n = 83). CONCLUSION: In eTNBC and mTNBC, PD-L1-positive status was associated with more favourable long-term outcomes, possibly due to tumour-intrinsic characteristics and/or the host immune response. The high proportion with de novo mTNBC may suggest enrolment bias and/or geographic variations in stage at diagnosis.